...the interface of immunity and metabolism, including LANCL2, NLRX1 and PLXDC2.Lead program BT-11, which targets LANCL2...

...lead product BT-11 for ulcerative colitis and Crohn’s disease; the first-in-class oral small molecule targets lanC like 2 (LANCL2)...

...it will go toward the Phase II inflammatory bowel disease trials of the first-in-class oral LANCL2...
...in 1H20 for ulcerative colitis and Crohn's, said Bassaganya-Riera. The company's pipeline also contains additional LANCL2...
...the financing, RTW’s Rod Wong and Perceptive’s Konstantin Poukalov joined Landos’ board. Targets: LANCL2 - LanC like 2...

...Landos Biopharma Inc. is developing a first-in-class LANCL2 agonist designed to provide improved convenience, efficacy and...
...binds to LANCL2, which leads to downstream activation of cAMP signaling and various anti-inflammatory pathways. LANCL2...
...midyear. According to BioCentury’s BCIQ database, there are no clinical stage IBD candidates that target LANCL2...

...the company files an IND for lead candidate BT-11 next year. BT-11 is an oral LanC like 2 (LANCL2)...
...the accelerator. Garabedian joined Landos’ board. Landos Biopharma Inc. , Blacksburg, Va. Alicia Parker BT-11 Landos Biopharma Inc. Xontogeny LLC LanC like 2 (LANCL2)...

...the company files an IND for lead candidate BT-11 next year. BT-11 is an oral LanC like 2 (LANCL2)...
...declined to disclose the number of companies in the accelerator. Garabedian joined Landos’ board. Virginia Li Xontogeny LLC LanC like 2 (LANCL2) BT-11 Landos...

...benzoimidazolylpyridine-based LANCL2 agonist that could help treat IBD. In silico screening of benzoimidazole analogs for LANCL2...
...followed by chemical synthesis and testing of hits in vitro yielded a compound that bound LANCL2...
...include testing the safety and efficacy of the compound in additional models of IBD. TARGET/MARKER/PATHWAY: LanC like 2 (LANCL2)...